Business Standard

Monday, December 23, 2024 | 04:40 PM ISTEN Hindi

Notification Icon
userprofile IconSearch

Zydus Lifesciences receives USFDA approval for Pitavastatin Tablets

Image

Capital Market

Zydus Lifesciences has received final approval from the United States Food and Drug Administration (USFDA) for Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg (USRLD: Livalo Tablets).

Pitavastatin is a HMG-CoA reductase inhibitor indicated as an adjunctive therapy to diet in adult patients with primary hyperlipidemia or mixed dyslipidemia to reduce elevated total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), apolipoprotein B (Apo B), triglycerides (TG), and to increase high-density lipoprotein cholesterol (HDL-C). It is also indicated for pediatric patients aged 8 years or older with heterozygous familial hypercholesterolemia (HeFH) to reduce elevated TC, LDL-C, and Apo B.

The drug will be manufactured at the group's formulation manufacturing facility at Moraiya.

 

Pitavastatin Tablets, 1 mg, 2 mg, and 4 mg had annual sales of USD 319 mn in the United States (IQVIA MAT Dec. 2022)

Powered by Capital Market - Live News

Disclaimer: No Business Standard Journalist was involved in creation of this content

Don't miss the most important news and views of the day. Get them on our Telegram channel

First Published: Feb 24 2023 | 8:47 PM IST

Explore News